RECKITT BENCKISER-SPON ADR Business Summary

Reckitt Benckiser-Spon ADR (RBGLY) operates as a global leader in the consumer goods sector, generating revenue through the manufacturing and distribution of high-demand health, hygiene, and nutrition products. The company’s business model is structured around three primary segments: Hygiene, which includes market-leading brands such as Lysol, Finish, and Air Wick; Health, featuring globally recognized labels like Mucinex, Durex, and Nurofen; and Nutrition, which is anchored by the Enfamil infant formula franchise. Revenue is primarily derived from high-volume sales to retail distributors, wholesalers, and direct-to-consumer e-commerce channels. Reckitt competes directly with diversified giants such as Procter & Gamble, Unilever, and Haleon. Within this competitive landscape, Reckitt occupies a specialized niche, maintaining the #1 or #2 global market position in the majority of its categories by focusing on high-margin, science-led consumer health and disinfectant solutions that command significant brand loyalty. The company’s executive leadership is headed by Chief Executive Officer Kris Licht, who assumed the role in 2023 after serving as the President of Reckitt’s Health Global Business Unit and Chief Customer Officer. Licht is supported by Chief Financial Officer Shannon Eisenhardt, a former Nike executive with deep expertise in consumer-centric financial strategy and capital allocation. The Board of Directors is chaired by Sir Jeremy Darroch, the former CEO of Sky, who provides strategic oversight on digital transformation and consumer engagement. While the modern corporate entity was formed by the 1999 merger of Reckitt & Colman and Benckiser NV, the current management team is focused on a post-2024 strategic pivot to optimize the portfolio by divesting non-core homecare assets. Major institutional shareholders, including BlackRock and Vanguard, remain influential in the company’s governance as it prioritizes high-growth investments in its consumer health and hygiene portfolios.